220 related articles for article (PubMed ID: 36168964)
1. Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of
Na SY; Kim BW; Kim MJ; Choe Y; Kim JS
Gut Liver; 2023 Sep; 17(5):722-730. PubMed ID: 36168964
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients.
Cho JH; Jeon SR; Kim HG; Jin SY; Park S
J Gastroenterol Hepatol; 2019 Apr; 34(4):700-706. PubMed ID: 30011083
[TBL] [Abstract][Full Text] [Related]
3. Tailored eradication
Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY
World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776
[TBL] [Abstract][Full Text] [Related]
4. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
Jung K; Jee SR; Lee MW; Koh M; Kim SJ; Lee J; Park MI
Helicobacter; 2024; 29(3):e13084. PubMed ID: 38717034
[TBL] [Abstract][Full Text] [Related]
6. An Economic Modeling Study of
Gweon TG; Kim JS; Kim BW
Gut Liver; 2018 Nov; 12(6):648-654. PubMed ID: 30037167
[TBL] [Abstract][Full Text] [Related]
7. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for
Cha B; Bang BW; Shin JB; Ko EJ; Ko W; Kwon KS; Shin YW; Suh YJ; Kim H
Scand J Gastroenterol; 2021 Sep; 56(9):1017-1022. PubMed ID: 34369255
[TBL] [Abstract][Full Text] [Related]
8. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for
Kim SY; Park JM; Lim CH; Lee HA; Shin GY; Choe Y; Cho YK; Choi MG
Gut Liver; 2021 Jul; 15(4):528-536. PubMed ID: 33376228
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
10. Tailored eradication strategy
Choi YI; Chung JW; Kim KO; Kwon KA; Kim YJ; Kim JH; Seo JY; Park DK
World J Gastroenterol; 2021 Aug; 27(31):5247-5258. PubMed ID: 34497448
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
Kim YJ; Chung WC; Kim DB
Helicobacter; 2021 Jun; 26(3):e12792. PubMed ID: 33650225
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.
Chang YW; Shin GY; Kim JW; Moon JC; Chang EJ; Oh CH; Jang JY
Dig Dis Sci; 2022 Apr; 67(4):1222-1230. PubMed ID: 33755825
[TBL] [Abstract][Full Text] [Related]
13. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens.
Woo HY; Park DI; Park H; Kim MK; Kim DH; Kim IS; Kim YJ
Helicobacter; 2009 Feb; 14(1):22-8. PubMed ID: 19191892
[TBL] [Abstract][Full Text] [Related]
14. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tailored
Cho JH; Jin SY; Park S
Expert Rev Anti Infect Ther; 2022 Jun; 20(6):923-929. PubMed ID: 34883037
[TBL] [Abstract][Full Text] [Related]
16. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
17. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin.
Lehours P; Siffré E; Mégraud F
BMC Gastroenterol; 2011 Oct; 11():112. PubMed ID: 22004003
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
20. Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
Han X; Yu X; Gao X; Wang X; Tay CY; Wei X; Lai B; Marshall BJ; Zhang X; Chua EG
Helicobacter; 2023 Aug; 28(4):e12985. PubMed ID: 37066609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]